NCT00368563 is a Phase 2/Phase 3 clinical trial of Helioblock SX in Dry Skin, sponsored by Loreal USA.

Who is sponsoring NCT00368563?

NCT00368563 is sponsored by Loreal USA.

What drugs are being tested in NCT00368563?

Interventions in NCT00368563: Helioblock SX.

Is NCT00368563 still recruiting?

NCT00368563 is currently completed. Last updated 10 February 2009.

Last reviewed 2009-02-10 · How we verify

NCT00368563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Capacitance and Transepidermal Water Loss Test to Determine the Ability of Sunscreen to Moisturize Skin

Completed Phase 2/Phase 3 Last updated 10 February 2009

What this trial tests

Phase 2/Phase 3 trial testing Helioblock SX in Dry Skin. Completed in 1 October 2006.

Timeline

1 August 2006

Primary endpoint
1 October 2006

1 October 2006

Quick facts

Lead sponsor	Loreal USA
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Start date	1 August 2006
Primary completion	1 October 2006
Estimated completion	1 October 2006
Sites	1 location across United States

Drugs / interventions tested

Helioblock SX — full drug profile →

Conditions studied

Dry Skin — all drugs for Dry Skin →

Sponsor

Loreal USA — full company profile →

Who can join

Adults 18 to 55, any sex, with Dry Skin.

Sponsor's own description

To evaluate the ability of 2 Helioblock SX Cream formulations to moisturize skin using capacitance and transepidermal water loss methodology

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other recruiting trials for Dry Skin

Currently open trials in the same condition.

NCT06800755 — Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00368563 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Loreal USA
Last refreshed: 10 February 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00368563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing